Once-weekly dulaglutide 1.5mg significantly improved HbA1c (-2.0%) and reduced body weight (-3.5 kg) at 12 months in type 2 diabetes patients who weren't adequately controlled by previous treatments.
-2.0% HbA1c at 12 monthsPatients whose diabetes was poorly controlled on previous medications saw a clinically meaningful 2.0% reduction in HbA1c after 12 months of weekly dulaglutide, with progressive improvement from the 6-month mark.
What the researchers found
HbA1c decreased significantly at both time points: -1.3% at 6 months (p<0.001) and -2.0% at 12 months (p<0.001). Body weight decreased by -2.0 kg at 6 months (p=0.002) and -3.5 kg at 12 months (p=0.001). A reduction in insulin dose was also observed in patients taking concurrent insulin.
The improvements were progressive — results at 12 months were better than at 6 months for both HbA1c and weight, suggesting continued benefit with ongoing treatment.
Why it matters
Clinical trials test drugs under ideal conditions with carefully selected patients, but real-world effectiveness can differ. This study confirms that dulaglutide delivers meaningful blood sugar and weight improvements in everyday clinical practice — in patients who have already failed other treatments. The progressive improvement from 6 to 12 months is reassuring for long-term use, and the insulin-sparing effect suggests dulaglutide may simplify complex diabetes regimens.
How the study worked
This retrospective study reviewed medical records of 50 type 2 diabetes patients from a single center who were inadequately controlled on previous antidiabetic medications and started on dulaglutide 1.5mg weekly. Data were collected at baseline, 6 months (50 patients), and 12 months (40 patients — 10 were lost to follow-up or discontinued). Primary outcomes were changes in HbA1c and body weight.
What this study cannot tell us
This is a small, single-center retrospective study without a control group, making it impossible to separate dulaglutide's effects from natural disease progression or concurrent treatment changes. Ten patients (20%) were lost between the 6- and 12-month assessments, which could introduce bias if those who dropped out had worse outcomes. The sample of 50 patients is too small for meaningful subgroup analyses. No adverse event data is reported in the abstract.
How to read the evidence
This is a small, single-center retrospective observational study without a control group. While the statistically significant improvements in HbA1c and weight are clear, the lack of randomization, control group, and blinding limit causal inference. The 20% dropout rate between 6 and 12 months is concerning. The evidence is useful for confirming real-world effectiveness but is lower quality than the randomized trials that originally established dulaglutide's efficacy.
When this study was published
Published in 2023, this study reflects real-world dulaglutide use during a period when the GLP-1 receptor agonist market was rapidly expanding. Newer agents with greater efficacy have since become more widely available.
The bigger picture
Dulaglutide was one of the first once-weekly GLP-1 receptor agonists to reach the market and helped establish the weekly injection format that semaglutide and tirzepatide later popularized. While newer GLP-1 drugs have shown even greater weight loss and HbA1c effects in large trials, dulaglutide remains widely prescribed — particularly in markets where newer agents are less available or more expensive. Real-world evidence like this study helps validate prescribing decisions for the millions of patients currently using this medication.
Questions still open
- How does the real-world effectiveness of dulaglutide compare to semaglutide and tirzepatide in similar patient populations?
- Why did 10 patients not continue to the 12-month assessment — was it related to side effects, efficacy, or access issues?
- Could the insulin dose reduction observed with dulaglutide lead to cost savings that partially offset the drug's expense?
Common questions
How much blood sugar improvement can I expect from dulaglutide?
How much weight will I lose on dulaglutide?
Read the original research
The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes.
Medicine and pharmacy reports, 96(1), 52-57
Citation
Ruda, Alexandru Ioan; Ciobanu, Dana Mihaela; Inceu, Georgeta; Rusu, Adriana; Roman, Gabriela. (2023). The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes.. Medicine and pharmacy reports, 96(1), 52-57. https://doi.org/10.15386/mpr-2425